Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells

Nature

Volumn 435, Issue 7038, 2005, Pages 108-114

  Chiu, Ya Lin ^a   Soros, Vanessa B ^a   Kreisberg, Jason F ^a,b   Stopak, Kim ^a,b   Yonemoto, Wes ^a   Greene, Warner C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; BLOOD; CELLS; ENZYMES; GENETIC ENGINEERING; RNA; VIRUSES;

HIGH MOLECULAR MASS (HMM); HUMAN IMMUNODEFICIENCY VIRUS (HIV); HYPERMUTATION; LOW MOLECULAR MASS (LMM);

MEDICAL PROBLEMS;

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CD4 ANTIGEN; DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE DEAMINASE; HIGH MOLECULAR MASS RIBONUCLEOPROTEIN COMPLEX; MITOGENIC AGENT; PROTEIN; RIBONUCLEASE; RIBONUCLEOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CEM15 PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; REPRESSOR PROTEIN; UBIQUITIN; VIF PROTEIN;

MEDICINE;

ARTICLE; CONTROLLED STUDY; CYTOPLASM; DEAMINATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; SEQUENCE ANALYSIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; CD4+ T LYMPHOCYTE; CELL LINE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ENVELOPE GENE; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR GENETICS; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RNA INTERFERENCE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; CYTOPLASM; ENZYME ACTIVATION; GENE PRODUCTS, VIF; GENES, ENV; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MITOGENS; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; MULTIPROTEIN COMPLEXES; NUCLEOSIDE DEAMINASES; ORGAN SPECIFICITY; PROTEINS; REPRESSOR PROTEINS; RIBONUCLEASES; RNA INTERFERENCE; UBIQUITIN; VIRUS REPLICATION;

EID: 18344372631     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03493     Document Type: Article

References (30)

1. Zack, J. A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222 (1990).
2. Korin, Y. D. & Zack, J. A. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72, 3161-3168 (1998).
3. Pierson, T. C. et al. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J. Virol. 76, 8518-8531 (2002).
4. Stevenson, M., Stanwick, T. L., Dempsey, M. P. & Lamonica, C. A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 9, 1551-1560 (1990).
5. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
6. Iarmuz, A. et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296 (2002).
7. Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10, 1247-1253 (2002).
8. Harris, R. S. et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809 (2003).
9. Mangeat, B. et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103 (2003).
10. Lecossier, D., Bouchonnet, F., Gavel, F. & Hance, A. J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112 (2003).
11. Zhang, H. et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98 (2003).
12. Stopak, K., de Noronha, C., Yonemoto, W. & Greene, W. C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12, 591-601 (2003).
13. Marin, M., Rose, K. M., Rozak, S. L. & Kabat, D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Med. 9, 1398-1403 (2003).
14. Sheehy, A. M., Gaddis, N. C. & Malim, M. H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Med. 9, 1404-1407 (2003).
15. Mariani, R. et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21-31 (2003).
16. Anant, S. & Davidson, N. O. Molecular mechanisms of apolipoprotein B mRNA editing. Curr. Opin. Lipidol. 12, 159-165 (2001).
17. Muramatsu, M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563 (2000).
18. Bransteitter, R., Pham, P., Scharff, M. D. & Goodman, M. F. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc. Natl Acad. Sci. USA 100, 4102-4107 (2003).
19. Yu, X. et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060 (2003).
20. Triques, K., & Stevenson, M. Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J. Virol. 78, 5523-5527 (2004).
21. Eckstein, D, A. et al. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 15, 671-682 (2001).
22. Newman, E. N. et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15, 166-170 (2005).
23. Turelli, P., Mangeat, B., Jost, S., Vianin, S. & Trono, D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303, 1829 (2004).
24. Bishop, K. N. et al. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14, 1392-1396 (2004).
25. Liddament, M. T., Brown, W. L., Schumacher, A. J. & Harris, R. S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14, 1385-1391 (2004).
26. Wiegand, H. L., Doehle, B. P., Bogerd, H. P. & Cullen, B. R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23, 2451-2458 (2004).
27. Zheng, Y. H. et al. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78, 6073-6076 (2004).
28. Stremlau, M. et al The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853 (2004).
29. + lymphocytes. Nature 426, 853-857 (2003).
30. Camaur, D. & Trono, D. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J. Virol. 70, 6106-6111 (1996).